<img height="1" width="1" style="display:none" src="https://www.facebook.com/tr?id=780280282443813&amp;ev=PageView&amp;noscript=1">
search

    Leap Therapeutics, Inc.

    verified_userVerify Profile
    Companies » Health Care » Pharmaceuticals & Biotechnology » Pharmaceuticals

    About Leap Therapeutics, Inc.

    Leap Therapeutics (NASDAQ: LPTX) is focused on developing targeted and immuno-oncology therapeutics. Leap's most advanced clinical candidate, DKN-01, is a humanized monoclonal antibody targeting the Dickkopf-1 (DKK1) protein, a Wnt pathway modulator. DKN-01 is in clinical trials in patients with esophagogastric, hepatobiliary, gynecologic, and prostate cancers. Leap's second clinical candidate, TRX518, is a humanized GITR agonist monoclonal antibody designed to enhance the immune system's anti-tumor response that is in advanced solid tumor studies. Source

    At A Glance

    • CAPITAL RAISE STATUS
      Not Currently Raising
    • FILING TYPE
      Public
    • PLATFORM TYPE
      NASDAQ
    • RAISED AMOUNT
      $X,XXX,XXX
    • PRE-MONEY EVAULATION
      $X,XXX,XXX
    • SIC CODE
      2834
    • NIN CODE
      ####
    • LEADERSHIP
      Chris Mirabelli, Ph.D.
    • FOUNDED
      2011
    • EMPLOYEES
      20
    • SECTOR
      Pharmaceuticals & Biotechnology
    • SUBSECTOR
      Pharmaceuticals

    Company Tags

    No articles found.

    Voyager Therapeutics, Inc.

    Voyager Therapeutics, Inc.

    Voyager Therapeutics is developing life-changing gene therapies for fatal and debi...

    Voyager Therapeutics is developing life-changin...

    Filing Type:    PU
    Millendo Therapeutics, Inc.

    Millendo Therapeutics, Inc.

    Millendo Therapeutics is a late-stage biopharmaceutical company primarily focused ...

    Millendo Therapeutics is a late-stage biopharma...

    Filing Type:    PU
    LoveBug Nutrition Inc.

    LoveBug Nutrition Inc.

    LoveBug Probiotics brings customers an award-winning range of probiotic supplement...

    LoveBug Probiotics brings customers an award-wi...

    Amount Raised:    $448,074.24
    Fundraising Status:    EC
    Filing Type:    CF
    Kala Pharmaceuticals, Inc.

    Kala Pharmaceuticals, Inc.

    Kala Pharmaceuticals, Inc. (Kala) is a biopharmaceutical company focused on the de...

    Kala Pharmaceuticals, Inc. (Kala) is a biopharm...

    Filing Type:    PU
    TG Therapeutics, Inc.

    TG Therapeutics, Inc.

    TG Therapeutics is a biopharmaceutical company focused on the acquisition, develop...

    TG Therapeutics is a biopharmaceutical company ...

    Filing Type:    PU
    Acacia Diversified Holdings, Inc.

    Acacia Diversified Holdings, Inc.

    Acacia Diversified Holdings, Inc., is an emerging hemp company, through its wholly...

    Acacia Diversified Holdings, Inc., is an emergi...

    Filing Type:    RA
    argenx SE

    argenx SE

    argenx is a clinical-stage biotechnology company developing a deep pipeline of dif...

    argenx is a clinical-stage biotechnology compan...

    Filing Type:    PU
    OncoSec Medical Incorporated

    OncoSec Medical Incorporated

    OncoSec Medical Incorporated is a clinical-stage biotechnology company focused on ...

    OncoSec Medical Incorporated is a clinical-stag...

    Filing Type:    PU
    Tyme Technologies, Inc.

    Tyme Technologies, Inc.

    Tyme Inc. is an emerging biotechnology company developing cancer therapeutics that...

    Tyme Inc. is an emerging biotechnology company ...

    Filing Type:    PU
    ©2025 National Investor Network. All Rights Reserved.